Aquestive Therapeutics, Inc.
AQST
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for theā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$5.99
Price+2.11%
$0.12
1Y
Price
Market Cap
$595.244m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-86.2%
EBITDA Margin-120.6%
Net Profit Margin-100.6%
Free Cash Flow MarginRevenue
$43.397m
-24.6%
1y CAGR-1.6%
3y CAGR-2.7%
5y CAGREarnings
-$68.979m
-56.3%
1y CAGR-143.9%
3y CAGR-102.2%
5y CAGREPS
-$0.71
-39.2%
1y CAGR-81.0%
3y CAGR-50.9%
5y CAGRBook Value
-$4.109m
$163.559m
Assets$167.668m
Liabilities$128.862m
DebtDebt to Assets
78.8%
-2.6x
Debt to EBITDAFree Cash Flow
-$50.944m
-41.8%
1y CAGR-129.6%
3y CAGR-81.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company